Navigation Links
Proteothera, Inc. Announces Scientific Advisors to Aid in Development of Novel Therapy for Acute Gout Attacks
Date:11/8/2015

ProteoThera, Inc., an early stage biotech platform company that is developing therapies for the local delivery of validated and FDA approved drugs, peptides, and small molecules to treat autoinflammatory diseases and tissue regeneration, today announced the team of scientific advisors who will guide the Company with their development of local delivery of a modified IL-1RA for the relief of pain for patients suffering from acute gout attacks.

“I believe that ProteoThera may be changing the paradigm for the traditional treatment of acute gout flares by potentially offering a safe and effective treatment for acute gout with an early onset of pain relief,” said Dr. Lee Simon, who serves as the Company’s acting Medical Director and lead scientific advisor. “The compilation of these renowned gout experts to serve as advisors for the acute gout therapy development program is a great step towards that goal.”

Advisors to ProteoThera’s acute gout therapy development program include the following experts:

  •     Lee Simon, M.D., Principal, SDG LLC, Former FDA Division Director, Division of Pulmonary, Allergy and Rheumatology Products
  •     Robert Terkeltaub, M.D., Professor of Medicine, University of California, San Diego
  •     Naomi Schlesinger, M.D., Professor of Medicine, Chief of Rheumatology, Rutgers University
  •     Joseph Flood, M.D., Columbus Arthritis Center

“We warmly welcome our new scientific advisors to the ProteoThera team,” said Patrick O’Donnell, President and Chief Executive Officer of ProteoThera. “I am confident that under guidance from this group of leaders in rheumatology with such varied foundations of expertise, our company will make great strides in furthering the development of our lead therapy and further prove out the significant value of our matrix-binding peptide technology platform for the local delivery of numerous commercially validated therapeutics.”

About ProteoThera, Inc.
ProteoThera, Inc. is an early stage biotechnology company that is advancing drug targeting technology. The Company's transformative platform technology, a proprietary tissue matrix-binding (MB) peptide technology, is being developed to improve clinical efficacy and safety of FDA approved and validated therapeutics to create a new paradigm in the treatment of autoinflammatory diseases and in tissue regeneration.

The MB targeting technology was developed at Brigham and Women’s Hospital and Harvard Medical School. The MB technology can generate new pharmacokinetic profiles for therapies, transforming systemically delivered drugs into locally or subcutaneous delivered proteins, peptides, and small molecules. ProteoThera’s focus on previously validated or approved therapies greatly de-risks the clinical, regulatory, and commercial pathways. By keeping therapies where they are needed to enable therapeutic effect, the MB platform may also improve the safety profile by reducing or eliminating side effects associated with whole-body systemic exposure.

ProteoThera’s first development priority is the use of PRT-1000 (MB - Interleukin 1 Receptor Antagonist (MB-IL1RA) for treatment of acute gout pain. IL1RA is a potent cytokine inhibitor, already FDA approved for systemic administration in rheumatoid arthritis. Gout is a large and growing market with total gout drug sales projected to double to more than $2 Billion by 2018 in the US and Europe.
###

Read the full story at http://www.prweb.com/releases/2015/11/prweb13068177.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved


Related medicine news :

1. Pixel Film Studios announces the release of FCPX Toolbox Volume 4 which includes Essential Editing Tools for Final Cut Pro X Users.
2. First Choice Emergency Room Announces Dr. Andrew P. Kretschmer as Medical Director of Spring, Texas Facility
3. National Hot Dog and Sausage Council Announces Official Policy On ‘Hot Dog as Sandwich’ Controversy
4. Imagequantify.Com Announces New Iqbot For Quantitative Analysis Of Histological Imaging Data: Dab Stain Analysis
5. The National Center for Homeopathy Announces Constantine Hering, MD Dedication Ceremony
6. IRIS Announces Start of 2nd Annual 30/30 Retinal Screenings Campaign
7. RJ Young Announces Key Leadership Promotions & Additions
8. MTI-GlobalStem Announces Collaboration for First Commercial In Vitro Test System for Human Neuroprotection in Proteopathic Diseases, Such As Alzheimer’s and Parkinson’s
9. Dr. Michael Feiz Announces a Successful Outcome for Needlescopic Surgery Streamed Live at the 2015 ASMBS Conference
10. Career Training Academy Announces Relocation, Expansion for New Kensington Campus
11. Above and Beyond Family Center Announces Premier Public Reception
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important ... problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , She developed ... darkness or restricted lighting. As such, it eliminates the need to turn on a ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along ... updates for the primary prevention of cardiovascular diseases during the 15th Annual ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The Visiting ... Day Market. Featuring a collection of specialty vendors and unique items from across the ... and quality-focused health and wellness services offered by the VNA. The boutique will ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... healthcare compliance program management, will showcase a range of technology and learning solutions ... Living (NCAL) Convention and Expo to be held October 14–18, 2017 at the ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
(Date:10/2/2017)... -- The Rebound mobile app is poised to become a ... of prescription drug addiction. The app empowers users to develop ... down their dosage in a safe, controlled manner while maximizing ... first 100,000 people to sign up will enjoy 3 months ... ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
Breaking Medicine Technology: